Clinical Trial Search

Primary: Insulin Sensitivity — 0.1; 0.07 mL/kg/min per uU/mL

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL

Primary: Insulin Sensitivity — 8.6; 6.2; 5.8; 4.8 mg/kg/min

Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Primary: Number of All Consented Participants — 12; 12 Participants

Primary: Change in Weekly Mean Blood Glucose From Week 4 to Week 16 — 4.6; 8.1; 29.5 mg/dL

Primary: Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12. — -18; -7.5 Events

Primary: Change in GAD65 Autoantibody Titer (DK Units/mL) — 247; 234; 193; 196 DK Units/mL

Primary: Feasibility of Usage — 168 minutes/week

Primary: Adverse Events — 2; 2 Serious adverse events

Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL

Primary: Change in Hemoglobin A1c — 2.67; 1.05 percentage change from baseline

Primary: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care — -0.16; -0.12 liters

Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL

Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87

Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population — -2.01; -1.75 percent — p=<0.0001

Primary: Change From Baseline in A1C at Week 24 — -0.59; -0.03 Percent — p=<0.001

Primary: Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit — 0.834; 0.775 nmol/L — p=0.048

Primary: Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl — -3.8 percentage of time

Primary: Change in Glycemic Control — 8.99; 8.20 % of glycated hemoglobin

Primary: Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months — -5.20; -4.83 nmol*min/L — p=0.33

Primary: Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months — 9.00; 6.81; 7.13; 7.26 percentage of glycosylated hemoglobin

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: Change in HbA1c — -0.25; -0.4 Percent — p=0.2539

Primary: Change in HgBA1c — 8.5; 8.7 percentage of glycosylated hemoglobin